Urology news for Saturday, October 3, 2026

Top 5 in urology

Updated Cochrane review: PSA screening modestly cuts prostate cancer deaths, overall mortality benefit uncertain Meta-analysis · BJU Int · 2026-10-02
An update of the Cochrane review pooling six randomized trials (789,086 participants) found PSA-based screening likely reduces prostate cancer-specific mortality (moderate-certainty evidence) but any effect on overall mortality remains uncertain, with low-certainty evidence of a small or null effect.
Why it matters: Provides the most current synthesis of screening trial evidence to inform shared decision-making conversations about PSA testing.
Freedom from biochemical recurrence at 5 years predicts low long-term metastasis risk Retrospective · Eur Urol Oncol · 2026-10-02
Pooled analysis of 3,120 men from 11 randomized trials found that men without biochemical recurrence at 5 years after high-dose radiotherapy had low 8-year metastasis and 10-year prostate cancer death risk, especially with intermediate-risk disease treated without long-term ADT.
Why it matters: Supports using 5-year BCR-free status as a meaningful reassurance milestone in post-radiotherapy surveillance discussions.
SAKK 06/19: adding intravesical BCG to perioperative chemoimmunotherapy in MIBC Phase 1-2 · MedPage Today · 2026-10-01
Primary analysis of the single-arm, open-label phase II SAKK 06/19 trial, which added intravesical recombinant BCG to perioperative chemoimmunotherapy in high-risk muscle-invasive bladder cancer.
Why it matters: An early-phase signal only: without a randomized control arm, the trial cannot show how much intravesical BCG adds.
Real-world data show similar survival across ARPI doublets, all better than docetaxel doublet Retrospective · JCO Oncol Pract · 2026-10-02
In over 9,100 US men with metastatic hormone-sensitive prostate cancer, abiraterone, apalutamide, and enzalutamide doublets each showed superior progression-free survival versus docetaxel doublets, with comparable overall survival among all regimens and no clear differences between ARPIs.
Why it matters: Reinforces that any ARPI doublet is a reasonable first-line choice over docetaxel doublet in real-world mHSPC practice.
Contrast-enhanced ultrasound guidance beats fluoroscopy for PCNL renal access RCT · Eur Urol Focus · 2026-10-02
In a 150-patient randomized trial, dual contrast-enhanced ultrasound guidance achieved higher first-attempt puncture success, faster tract establishment, shorter hospital stay, and less blood loss than fluoroscopy during PCNL, with similar complication rates.
Why it matters: Offers a radiation-free alternative for renal access during PCNL with potentially better efficiency and safety.

Prostate cancer news

SOAR phase 2 trial: PSMA-directed salvage therapy without ADT feasible in oligorecurrent prostate cancer Phase 1-2 · UroToday · 2026-10-02
The SOAR phase 2 trial evaluated PET-defined metastasis-directed therapy without androgen deprivation in men with oligorecurrent prostate cancer, reporting on feasibility and outcomes of this ADT-sparing approach.
Why it matters: Supports an ADT-sparing strategy for carefully selected oligorecurrent patients, though this duplicates a prior item on the same trial.
FDA clears next-gen SpaceOAR Flex hydrogel rectal spacer FDA clearance · Renal & Urology News · 2026-10-01
The FDA has cleared an updated formulation of the SpaceOAR hydrogel rectal spacer used during prostate radiotherapy to reduce rectal radiation exposure.
Why it matters: Radiation oncologists and urologists coordinating prostate RT may see this updated spacer option become available for patients.
POPART trial reports outcomes of postoperative SBRT to prostate bed for biochemical recurrence Prospective · UroToday · 2026-10-01
A prospective multicenter trial (POPART) presented at ASTRO 2026 evaluated stereotactic body radiotherapy delivered to the prostate bed after prostatectomy for biochemical recurrence.
Why it matters: SBRT to the prostate bed could offer a shorter-course alternative to conventional fractionated salvage radiotherapy.
Multicenter study evaluates AI risk classification for prostate cancer detection on biparametric MRI Retrospective · UroToday · 2026-10-01
A multicentre evaluation assessed an artificial intelligence risk classification tool for detecting clinically significant prostate cancer using biparametric MRI.
Why it matters: AI-assisted MRI interpretation could help standardize prostate cancer detection across centers with varying radiologist experience.
Review examines whether PI-RADS scoring performs equally well across racial groups Review · UroToday · 2026-10-01
A narrative review analyzed whether the Prostate Imaging Reporting and Data System (PI-RADS) has equivalent predictive performance for clinically significant cancer in Black versus White men.
Why it matters: Raises questions about potential racial disparities in MRI-based prostate cancer risk stratification that could affect biopsy decisions.
Author commentary discusses surgical management of PSMA PET-positive lymph nodes in prostate cancer Review · UroToday · 2026-10-01
A Beyond the Abstract piece discusses considerations for surgically managing lymph nodes identified as positive on PSMA PET imaging in prostate cancer patients.
Why it matters: Highlights ongoing uncertainty about how to act on PSMA PET-detected nodal disease, an increasingly common clinical scenario.
Small phase 2 trial: PSMA PET-guided salvage therapy without ADT feasible in oligorecurrence Phase 1-2 · JU Open Plus · 2026-10-01
In 20 men with PET-defined oligorecurrent prostate cancer after prostatectomy, metastasis-directed therapy without androgen deprivation produced a 50% PSA decline in 40% at 6 months, with 12-month ADT-free survival around 71%.
Why it matters: Suggests a subset of oligorecurrent patients may be able to defer ADT using MDT alone, though pathology at salvage lymph node dissection often showed more extensive disease than PET predicted.

Bladder cancer news

FDA grants priority review to durvalumab plus enfortumab vedotin for MIBC FDA action · Renal & Urology News · 2026-10-02
The FDA has granted priority review to a combination regimen of durvalumab and enfortumab vedotin for muscle-invasive bladder cancer, a regulatory step already reported for the same combination in the metastatic setting.
Why it matters: If approved for MIBC, this would extend the regimen into earlier-stage perioperative treatment.
Global survey: most high-risk NMIBC patients offered cystectomy refuse surgery Retrospective · BJU Int · 2026-10-03
In a multinational survey of 359 physicians on 2,583 patients with high-risk NMIBC, radical cystectomy was offered to 20% of BCG-treated patients but 68% refused, mainly citing quality of life, stoma aversion, and surgical safety concerns.
Why it matters: Highlights a real-world gap between guideline-recommended cystectomy and patient acceptance, reinforcing demand for effective bladder-sparing options.
Event-free and progression-free survival fall short as OS surrogates in BCG-naive HR-NMIBC Retrospective · World J Urol · 2026-10-03
An 18-center study of 3,384 patients with BCG-naive high-risk NMIBC found adequate BCG exposure improved overall survival, but pseudo-trial-level surrogacy for OS was moderate (R2 0.60 for PFS, 0.51 for EFS), below the prespecified adequacy threshold.
Why it matters: Raises caution about relying on EFS or PFS as primary endpoints in NMIBC immunotherapy trials without OS confirmation.
Phase 1 trial: gemcitabine plus BCG retreatment shows high early response in BCG-exposed NMIBC Phase 1-2 · J Urol · 2026-10-02
In a 25-patient dose-escalation trial, alternating intravesical gemcitabine and BCG in BCG-exposed high-grade NMIBC was well tolerated with no dose-limiting toxicities, and 96% achieved complete clinical response at 6 months; a phase 3 trial comparing this combination to BCG alone is now underway.
Why it matters: Signals a potential strategy to improve BCG retreatment efficacy, pending confirmatory phase 3 data.
FDA proposes reclassifying blue light cystoscopy systems from Class III to Class II FDA action · UroToday · 2026-10-01
The FDA has proposed reclassifying blue light cystoscopy systems used for bladder cancer detection from Class III to Class II devices, a regulatory change welcomed by the manufacturer.
Why it matters: Reclassification could ease future device approvals and potentially expand access to blue light cystoscopy for NMIBC detection.
NCCN Bladder Cancer guidelines list gemcitabine intravesical system for BCG-unresponsive papillary-only NMIBC Guideline · NCCN · 2026-10-01
The NCCN Bladder Cancer guidelines (current Version 3.2026) list the gemcitabine intravesical system (Inlexzo) as a category 2A option for BCG-unresponsive high-risk NMIBC with Ta/T1 papillary-only disease without CIS, in addition to its listing for CIS with or without papillary tumors.
Why it matters: Extends a bladder-sparing option to the papillary-only BCG-unresponsive population, which joins the other agents listed for this setting; payer coverage commonly follows NCCN listing.
Preoperative kidney impairment loses prognostic significance after adjusting for cancer stage in cystectomy cohort Retrospective · Clin Genitourin Cancer · 2026-10-01
In 396 radical cystectomy patients, reduced eGFR was linked to worse recurrence-free and overall survival in age/sex-adjusted models, but this association was substantially attenuated after adjusting for pathologic stage and treatment factors.
Why it matters: Suggests preoperative renal function may be a marker of more advanced disease rather than an independent prognostic factor, relevant for risk counseling before cystectomy.
Urine methylation assay shows high sensitivity for detecting and monitoring urothelial cancer Prospective · JAMA Netw Open · 2026-09-30
A multicenter prospective study of a urine-based AL021918.2/vimentin methylation assay in over 2,300 patients found sensitivities around 91% and specificities around 90% for urothelial carcinoma detection and surveillance.
Why it matters: Could offer a noninvasive alternative or adjunct to cystoscopy and cytology for bladder cancer detection and surveillance.
ctDNA testing after cystectomy rose steadily since Medicare coverage but remains uncommon Retrospective · Urol Oncol · 2026-09-30
Claims data from 1,995 US bladder cancer patients undergoing radical cystectomy show ctDNA testing utilization increased from 4 to 34 tests per 1,000 patient-months between 2022 and 2025, with only 17% ever tested; median cost was about $4,178 with minimal out-of-pocket cost.
Why it matters: Highlights the gap between guideline interest in ctDNA-guided surveillance and actual real-world adoption after cystectomy.

Kidney cancer news

Older age, unmarried status, and non-White race linked to lower use of adjuvant therapy after nephrectomy Retrospective · Urol Oncol · 2026-10-02
Among 6,497 SEER-identified patients eligible for adjuvant systemic therapy after nephrectomy for renal cell carcinoma, only 17.9% received it, with significantly lower uptake among those age 65 or older, unmarried, or non-Caucasian, and these factors compounded when combined.
Why it matters: Highlights disparities in guideline-concordant adjuvant therapy uptake that may warrant targeted outreach efforts.
Delaying nephrectomy beyond 3 months linked to higher cancer death risk in pT1b-2 RCC Retrospective · BJU Int · 2026-09-30
In a SEER analysis of over 16,000 patients with pT1b-2N0M0 RCC, time to surgery beyond 3 months was associated with a 1.3-fold higher cancer-specific mortality, with a dose-response effect worsening beyond 6 months; the association was not seen in non-clear cell RCC.
Why it matters: Supports avoiding unnecessary surgical delay in localized RCC, particularly for clear cell histology.
Final KEYNOTE-427 data show PD-L1 and gene profile predict pembrolizumab response in RCC Phase 1-2 · Ann Oncol · 2026-09-30
Long-term follow-up of first-line pembrolizumab monotherapy in advanced RCC found T-cell inflamed gene expression and PD-L1 CPS positively associated with response, while baseline detectable ctDNA predicted shorter overall survival.
Why it matters: Biomarker data could eventually help select patients most likely to benefit from single-agent checkpoint therapy in RCC.
FDA expands Welireg label for additional kidney cancer indication FDA action · Zacks Investment Research · 2026-09-28
Merck's belzutifan (Welireg) received an expanded FDA label covering a new indication in kidney cancer.
Why it matters: Broader labeling may extend access to belzutifan for additional renal cell carcinoma patient populations.
Multicenter study finds 18% discordance between renal mass biopsy and final surgical pathology Retrospective · World J Urol · 2026-09-29
Among 1,301 patients from the UroCCR registry, renal mass biopsy showed an 18% overall discordance rate with surgical pathology (3.7% for malignancy, 8.4% for subtype, 5.7% non-diagnostic), with cystic tumors linked to higher discordance and greater tumor complexity linked to lower discordance.
Why it matters: Quantifies real-world limitations of renal mass biopsy that should inform counseling before active surveillance or ablation decisions.
Meta-analysis: PFS and response rate weakly predict overall survival in mRCC trials Meta-analysis · UroToday · 2026-09-28
A systematic review and meta-analysis found that progression-free survival and objective response rate are weak surrogates for overall survival across metastatic renal cell carcinoma trials.
Why it matters: Reinforces caution when using surrogate endpoints alone to judge treatment benefit in RCC trials.
Young-onset RCC shows higher survival and more germline mutations than older-onset disease Retrospective · Clin Genitourin Cancer · 2026-09-29
In a retrospective cohort of 812 nephrectomy patients, those aged 46 or younger with RCC had higher 5-year overall survival (92.4% vs 80.9%) and more frequent germline alterations in FANCI, POLD1, PTCH1, and RINT1 versus older patients.
Why it matters: Suggests germline testing may be worth considering in younger RCC patients and that age at onset carries prognostic information.
FDA approves belzutifan-lenvatinib for ccRCC after PD-1/PD-L1 therapy FDA approval · Renal & Urology News · 2026-09-28
The FDA approved the combination of belzutifan and lenvatinib for advanced clear cell renal cell carcinoma following prior immunotherapy, based on trial data supporting the regimen in this setting.
Why it matters: Adds another approved option for RCC patients who progress after checkpoint inhibitor therapy.

Upper tract urothelial carcinoma news

CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

EAU panel recommends centralized care to improve testicular cancer outcomes Guideline · UroToday · 2026-09-25
A European Association of Urology guidelines panel report argues that treatment at higher-volume centers is associated with better outcomes for testicular cancer patients, supporting centralization of care.
Why it matters: Referral pathways and case volume may influence outcomes in a highly curable cancer where errors have long-term consequences.

Endourology and stone disease news

Meta-analysis identifies risk factors for failed ureteroscope access before stone treatment Meta-analysis · J Endourol · 2026-09-30
Pooling 22 studies and nearly 8,750 procedures, primary ureteroscopic access failure occurred in 11% of cases; younger age, male sex, and proximal stone location increased risk, while thinner scopes and prior ipsilateral stone surgery were protective.
Why it matters: Helps identify patients who may benefit from prestenting or pretreatment to avoid failed access and staged procedures.
CT slice thickness biases stone-free rate assessment after RIRS Retrospective · World J Urol · 2026-09-28
In a retrospective cohort of 145 patients after retrograde intrarenal surgery, reconstructing CT images at 5-mm versus 1-mm slice thickness shifted 24% of patients to a more favorable stone-free grade, with no downgrades.
Why it matters: Reported stone-free rates depend heavily on CT reconstruction protocol, complicating comparisons across studies and centers.

BPH and male LUTS news

Network meta-analysis: vibegron reduces OAB symptoms as BPH add-on, no clear edge over mirabegron Meta-analysis · World J Urol · 2026-09-29
A Bayesian network meta-analysis of 18 trials found vibegron and mirabegron both reduced micturition frequency and urgency as add-on therapy in alpha-blocker-treated men with BPH and persistent OAB, but indirect comparisons showed no significant advantage of vibegron over mirabegron.
Why it matters: Confirms beta-3 agonists are a reasonable add-on for persistent storage symptoms in men on alpha-blockers, without evidence to prefer one agent.
Meta-analysis supports HoLEP safety in patients on antithrombotic therapy Meta-analysis · UROsource · 2026-09-28
An updated systematic review and meta-analysis found HoLEP to be a safe option for BPH surgery in patients receiving antithrombotic medications.
Why it matters: Supports continuing or minimally interrupting antithrombotics when performing HoLEP in appropriately selected patients.

Female pelvic medicine and neurourology news

AMA creates Category I CPT codes for implantable tibial neuromodulation in urge incontinence Policy · Urology Times · 2026-10-02
The AMA has issued dedicated Category I CPT codes for implantable tibial neuromodulation devices used to treat urgency urinary incontinence, moving the procedure out of unlisted-code billing.
Why it matters: New Category I codes typically improve payer recognition and reimbursement consistency for this neuromodulation option.
Lead migration after sacral neuromodulation more common with one device brand in single-center study Retrospective · Neurourol Urodyn · 2026-10-01
Among 445 patients undergoing sacral neuromodulation, 7.9% had confirmed lead migration; Axonics devices were associated with higher odds of migration than Medtronic devices, and all cases of large migration occurred with Axonics leads.
Why it matters: Device-specific migration risk may inform counseling and postoperative monitoring protocols for SNM patients.

Reconstruction and trauma news

Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.
Novel laparoscopic technique described for refractory piriformis-related pelvic pain Retrospective · J Endourol · 2026-09-26
A retrospective series of 200 patients across multiple institutions describes a transgluteal laparoscopic piriformis muscle transection technique for chronic pelviperineal pain syndrome, reporting technical feasibility with low morbidity and short hospital stay.
Why it matters: Introduces a minimally invasive surgical option for a difficult-to-treat and underrecognized cause of chronic pelvic pain.
Advances in artificial urinary sphincter technology Interview · Urology Times · 2026-09-14
Andrew Peterson, MD, on electronic sphincter innovations for post-treatment incontinence.
Why it matters: Relevant to survivorship care after prostatectomy and radiation.

Men's health news

Mediterranean diet adherence linked to differences in sperm DNA methylation patterns Retrospective · Andrology · 2026-09-30
A cross-sectional study of 60 healthy men found 42 differentially methylated CpG sites in sperm DNA comparing high versus low adherence to the Mediterranean diet, independent of age, smoking, and BMI.
Why it matters: Adds mechanistic evidence for how diet may influence sperm epigenetics, though clinical significance for fertility remains unclear.
PCF-sponsored consensus proposes cardiovascular risk triage schema for men on ADT/ARPi therapy Review · JCO Oncol Pract · 2026-09-29
A narrative review and clinician-industry consensus proposes a three-tier (high/intermediate/low) point-of-care schema to identify prostate cancer patients on hormone therapy who need cardiovascular referral, based on prior CVD events and risk-factor control.
Why it matters: Offers a practical framework for urologists to flag cardiovascular risk in ADT/ARPi patients before formal validation studies are completed.
Placebo injection response notably high across Peyronie's disease trials Retrospective · Renal & Urology News · 2026-09-28
An analysis of Peyronie's disease clinical trials found substantial improvement in placebo-injected control groups, complicating interpretation of active treatment effect sizes.
Why it matters: High placebo response rates in Peyronie's trials should temper enthusiasm for reported treatment effects and inform trial design.

Pediatric urology news

Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Offers a technical strategy to reduce early morbidity and emergency readmissions after a common pediatric reconstructive procedure.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.
New reference curves define expected residual hydronephrosis after pyeloplasty Retrospective · World J Urol · 2026-09-27
In 566 renal units after pyeloplasty, postoperative APD reference curves were built from units without recurrence. Renal pelvic APD above the 90th centile curve was linked to a much higher reoperation rate (11.7% vs 0.8%).
Why it matters: Offers an objective benchmark to decide which children with residual postoperative dilation need closer follow-up versus reassurance.
Insurance status and timing linked to orchiectomy odds after testicular torsion in NY state Retrospective · J Pediatr Urol · 2026-09-27
Among 4,159 children with testicular torsion in New York State over 15 years, 26% underwent orchiectomy; government or self-pay insurance and presentation timing were associated with higher orchiectomy odds, with effects varying by age group.
Why it matters: Points to potential access or systems-level disparities affecting testicle salvage rates that may warrant institutional review.

Practice and policy news

Southland NZ urology service faces collapse as surgeries continue to be cancelled News · 1News · 2026-10-01
Local reporting describes ongoing fears that Southland's urology service could collapse amid continued surgery cancellations, a story previously covered on this site.
Why it matters: Illustrates ongoing workforce and capacity strain affecting urology service delivery internationally.
Southland, NZ urology service warns of collapse amid surgery cancellations News · RNZ · 2026-09-30
Local reporting describes concerns that a regional urology service in Southland, New Zealand could collapse as surgeries are being cancelled, reflecting ongoing workforce and access strain.
Why it matters: Illustrates how urology workforce shortages can threaten service continuity even in developed health systems.
Southland, NZ clinicians again warn urology services are at risk of collapse News · whatsoninvers.nz · 2026-09-30
Local doctors reiterated concerns that the Southland, New Zealand urology service faces collapse amid ongoing surgery cancellations and staffing strain.
Why it matters: Highlights persistent workforce and access pressures facing urology services in some regions.
Report alleges Trump administration delayed release of USPSTF recommendations News · MedPage Today · 2026-09-29
MedPage Today reports the administration suppressed or delayed publication of US Preventive Services Task Force recommendations, raising concerns about screening guidance transparency.
Why it matters: USPSTF recommendations, including on PSA screening, guide payer coverage and practice; delays could affect prostate cancer screening policy.
Urology waiting list backlog persists despite fewer long delays News · European Medical Journal · 2026-09-29
A report finds that while the proportion of very long urology waits has fallen, overall waiting list burden for urology patients remains high.
Why it matters: Highlights ongoing capacity strain in urology services relevant to workforce and access planning.

More urology news

ECOG-ACRIN opens trial of bipolar androgen therapy sequencing in mCRPC Trial opening · ClinicalTrials.gov · 2026-10-01
A phase II/III trial will compare high-dose testosterone (bipolar androgen therapy) followed by darolutamide against usual care in 432 patients with metastatic castration-resistant prostate cancer.
Why it matters: Bipolar androgen therapy is an active area of investigation for resensitizing castration-resistant tumors to androgen pathway agents.
Phase 3 trial opens testing [177Lu]Ludotadipep in metastatic CRPC Trial opening · ClinicalTrials.gov · 2026-10-01
A new phase 3 trial sponsored by FutureChem will randomize 114 patients with metastatic castration-resistant prostate cancer to a radioligand therapy, with radiographic progression-free survival as the primary endpoint.
Why it matters: Represents continued expansion of PSMA-targeted radioligand therapy options in mCRPC beyond currently approved agents.
Phase 1-2 trial opens testing REGN21353 alone or with nezastomig in mCRPC Trial opening · ClinicalTrials.gov · 2026-09-30
A new phase 1-2 study will evaluate experimental agent REGN21353, alone or combined with nezastomig (and sarilumab in some participants), in previously treated metastatic castration-resistant prostate cancer. Planned enrollment is 192 patients.
Why it matters: Adds another bispecific/immunotherapy combination trial for heavily pretreated mCRPC patients who may be candidates for trial referral.
Pivotal trial opens for GRPR-targeted PET imaging agent in prostate cancer Trial opening · Urology Times · 2026-09-28
A pivotal clinical trial has launched to evaluate a GRPR-targeted PET imaging agent for prostate cancer, an alternative molecular target to PSMA.
Why it matters: New imaging targets beyond PSMA could expand options for staging and recurrence detection.
Industry and academic GU oncology trials stop early for different reasons Retrospective · Urology · 2026-09-27
Analysis of 1,597 phase II-III genitourinary oncology trials on ClinicalTrials.gov found 27.9% terminated early; academic trials mainly failed from poor accrual while industry trials stopped more often for strategic, regulatory, or interim efficacy/futility reasons.
Why it matters: Highlights structural differences in why GU oncology trials fail, relevant to trial design and site participation decisions.

Loading today's edition…